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Taiwanwas used in this study. There are three screening tools: 1) Pap smear alone;
2) HPV DNA testing followed by Pap smear triage; and 3) self-sampling for HPV
testing followed by Pap smear triage. Self-sampling for HPV testing strategy is
annual, and another strategies of screening intervals are annually, every 3 years,
and every 5 years. The model parameters are collected from the published refer-
ences and the health-related governments in Taiwan. Outcomemeasures included
life expectancy, quality-adjusted life years (QALYs), lifetime costs, and incremental
cost-effectiveness ratios (ICERs). Probabilistic sensitivity analyses (PSAs) were con-
ducted to assess parameter uncertainty. RESULTS: When three times GDP per
capita is used as the decision threshold, and all seven screening strategies were
cost-effective compared with the no-screening strategy. Compared with the pri-
mary screening strategy (an annual Pap smear), self-samplingHPV testing followed
by Pap smear triage, HPV DNA testing followed by Pap smear triage every 5 years
and every 3 years were cost-effective. CONCLUSIONS: Self-sampling for HPV testing
followed by Pap smear triage is one of the cost-effective screening strategies in Taiwan.
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OBJECTIVES:Gefitinib is an effective targeted therapy for a subset of non-small cell
lung cancer (NSCLC) patients, although its cost-effectiveness remains controver-
sial.. This study used national health insurance claims data to evaluate the cost-
effectiveness of gefinitib in patients with NSCLC in Taiwan. METHODS: Using
claims data and enrollment record from the 2002-2009 National Health Insurance
Research Database (NHIRD) in Taiwan, we identified lung cancer patients via the
ICD-9-CM codes.We then used ICD-9-CM and billing codes to identify patients who
had received chemotherapy containing plantinum-based regimens followed by
taxane-based regimens between November 1, 2004 and October 31, 2007. We de-
fined the index date as the date of 1st claim for taxane-based chemotherapy and
limited the observational period for cost and survival to 2 years after index date.We
further classified these patients into two groups: those who had subsequently
received gefitinib vs those had not. We determined survival status by using a pre-
viously developed algorithm using the enrollment file of the NHIRD and converted
direct medical costs to 2011 US dollars. We then calculated the net benefit for each
patient by applying various willingness-to-pay (WTP) values and employed the net
benefit regression approach to assess the cost-effectiveness of gefitinib. RESULTS:
We identified 2555 lung cancer; 979 (38%) had received gefitinib during our study
period. The average cost (standard deviation) were 64150(29482) USD for the ge-
fitinib users and 35925(27360) for non-users. The average survival was 487 days
(228) for the gefitinib users and 291 days (248) for non-users. Net benefit regression
suggested that gefitinib is cost-effective at WTP 53,000 USD/life-year or higher.
CONCLUSIONS: Among lung cancer patients who started with platinum-based
chemotherapy, followed by taxane-based regimen, adding gefitinib to chemother-
apy is likely to be cost-effective.
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OBJECTIVES: To evaluate the cost-utility of stage III colorectal cancer patients re-
ceiving either capecitabine-based or 5-FU/LV-based adjuvant treatments from the
societal perspective.METHODS: The data used in this research is being reported in
another study (Health Related Quality of Life, Direct and Indirect Cost Analysis of
Stage III Colorectal Cancer Patients Receiving Different Adjuvant Chemotherapy
Treatments in Taiwan). Direct and indirect costs, including productivity loss of
patients and their accompanying persons caused by receiving outpatient or inpa-
tient services, were involved in this study. Propensity score matching was used to
reduce selection bias and avoid endogenous problems between two groups of pa-
tients. The perspective adopted in this analysis was that of a society in Taiwan. All
costs were expressed in 2011 New Taiwan dollars (1 USD is about 30 NTD). Utility
value for the health states were derived by mapping the 16 dimensions of EORTC
QLQ-C30 onto the EQ-5D based on the published literature (McKenzie and van der
Pol, 2009). RESULTS: After propensity score matching, a total of 219 patients were
included in the analyses. There are 109 in the capecitabine-based treatment and
110 in the 5-FU/LV-based treatment. Over the study period of 6months, the average
cost of capecitabine-based treatment per patient was NT$220,576.3 while yielding
0.47 quality-adjusted life years (QALY). On the other hand, the average cost of
5-FU/LV-based treatment was NT$566,832.1 with 0.42 QALY. Between these two
adjuvant treatments, the capecitabine-based treatment was dominant.
CONCLUSIONS: As opposed to existing studies, cost and HRQoL data were directly
obtained from patients. Thus, based on patient-level information and the from the
societal perspective, our study showed that capecitabine-based treatment not only
saved costs but also improved quality-adjust life year compared with 5-FU/LV-
based treatment in the adjuvant treatment of stage III colorectal cancer in Taiwan.
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OBJECTIVES: Lung cancer is the common cause of cancer death in developing
countries. In Thailand, lung cancer, including non-small cell lung cancer (NSCLC)
ranks third of 10 leading sites of cancers. NSCLC has a poor prognosis which has an
effect on quality of life of both individual patients and their family. Understanding
the quality of life andhealth utility for lung cancer is important; however, little data
are available in Thailand. This study aimed to measure baseline health utility
among advance NSCLC patients before treated with first-line chemotherapy.
METHODS: A prospective cohort study was implemented in Maharaj Nakorn
Chiang Mai hospital which is a medical teaching hospital located in the north of
Thailand. A variety of first-line chemotherapy regimens were available for treat-
ment. In this study, we included patients aged 18 or above, diagnosed with NSCLC
with stage IIIB and IV, had performance status (ECOG) 0-1, and were scheduled to
receive first-line chemotherapy. The data were collected from January to March
2012. Utility was measured using EuroQoL Thai version. The data were collected
while patients visited outpatient oncology clinic. Descriptive statistics were used
for data analyses. RESULTS: During three months period, 24 patients were in-
cluded. Eight patients were NSCLC stage IIIB while 16 were stage IV. Mean utility
value of overall NSCLC, NSCLC stage IIIB and NSCLC stage IV at baseline before
receiving first-line chemotherapy were 0.419, 0.473 and 0.392, respectively.
CONCLUSIONS: Utility values of patients with advanced NSCLC are likely to be
downward due to the severity of disease; therefore, choosing the appropriate first-
line chemotherapy regimen might need to consider the quality of life of patients.
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OBJECTIVES: Benefits of treatment are often expressed as quality-adjusted life
years (QALYs). A QALY attempts to capture benefit in terms of both quantity of
survival and quality of life (QoL). Where appropriate data has not been captured in
a trial context, other methods need to be applied. The aim of this study was to
capture QoL data in the form of health state utilities, ranging from 0 (dead) to 1 (full
health), for outcomes associated with receiving therapy for rel/ref HL and sALCL.
These utilities could be used to support economic evaluation of future treatments.
METHODS: Health state descriptions or ‘vignettes’ were developed (with patient
and clinician input) depicting the burden associated with various stages of rel/ref
HL or sALCL, degree of disease response (complete [CR] or partial response, stable
or progressive disease), and adverse events (AE) experienced (B-symptoms, acute/
chronic graft-versus-host disease [GVHD], grade I/II or grade III peripheral sensory
neuropathy). Vignettes were then valued by 75 members of the general public in
Taiwan, Thailand, and South Korea using the time trade-off (TTO) methodology to
elicit utility values. RESULTS:Disease experience was associated with a significant
decline in QoL. Even a CR demonstrated a notable negative impact on QoL (Taiwan
0.597, Thailand 0.728, South Korea 0.827). The experience of any AE was associated
with substantial disutility, themost burdensome generally being acute GVHD (Tai-
wan 0.199, Thailand 0.124, South Korea 0.347). Additionally, progressive disease
was valued as having a very severe impact on QoL (Taiwan 0.229, Thailand 0.071,
South Korea 0.317).CONCLUSIONS: Experience of rel/ref HL and sALCL is viewed as
potentially devastating by individuals in all three countries. However, variations do
exist between regions, suggesting that individuals may approach the TTO exercise
differently. The results of this study may have important implications for the eco-
nomic evaluation of future treatments.
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OBJECTIVES: To investigate the cancer patients’ CAM disclosure to the health care
provider.METHODS: The study was designed as a questionnaire based, cross sec-
tional analysis. A prevalence based sample of 393 cancer patients admitted to the
oncology ward at Penang General Hospital was hereby selected for the study.
RESULTS: Of 393 patients, 184 (46.1%) were identified as CAM users and among
them126 (68.5%)were actively reported to use one ormore types of CAMat the time
of interview. CAMdisclosure rate was 43%, while only in 33.7% cases, patients been
asked by their doctors on the CAM use. The most common reason of CAM non-
disclosure was ‘not important for doctors to know about CAM’ 63 (34.2%). Among
other reasons were, ‘doctors never asked about CAM’ 15(8.2%), ‘doctors have little
knowledge about CAM’ 9(5.9%), ‘fear of CAMdisapproval by the doctors’ 8(4.3%) and
fear of termination of therapy by the doctors’ 6(3.3%). Among the demographic
variables patients having a history of regular health checkups before cancer diag-
nosis were tend to discuss their CAM use with the doctors (r0.16, p0.02). Per-
ceived severity of side effects due to conventional therapies was positively corre-
lated (r0.18, p0.014) with CAM disclosure. Patients who received
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